

Edgewise reports Phase 2 EDG-7500 data in thick heart muscles, showing symptom, biomarker, and heart function improvements.
You can purchase shares of Edgewise Therapeutics (NASDAQ:EWTX) through any online brokerage.
Other companies in Edgewise Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Edgewise Therapeutics has a consensus price target of $46.69.
The stock price for Edgewise Therapeutics (NASDAQ: EWTX) is $38.87 last updated November 5, 2026 at 4:00 PM EST.
There are no upcoming dividends for Edgewise Therapeutics.
Edgewise Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Edgewise Therapeutics.
Edgewise Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400....